A number of other equities analysts have also recently weighed in on RCEL. BTIG Research reissued a buy rating and set a $8.00 price objective on shares of AVITA MED LTD/S in a report on Thursday, June 18th. Oppenheimer started coverage on AVITA MED LTD/S in a research note on Monday, June 15th. They issued a buy rating and a $9.00 price target on the stock. Zacks Investment Research cut AVITA MED LTD/S from a buy rating to a hold rating in a research note on Tuesday, June 23rd. Finally, Lake Street Capital reaffirmed a buy rating and issued a $12.00 price target on shares of AVITA MED LTD/S in a research note on Thursday, March 5th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $8.88.
Shares of NASDAQ RCEL opened at $30.54 on Friday. The stock has a market cap of $560.31 million, a price-to-earnings ratio of -78.31 and a beta of 1.23. The company has a current ratio of 15.36, a quick ratio of 15.22 and a debt-to-equity ratio of 0.03. AVITA MED LTD/S has a 1-year low of $5.50 and a 1-year high of $55.35. The stock’s 50-day moving average is $6.19 and its 200 day moving average is $7.40.
AVITA MED LTD/S Company Profile
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin.
Featured Story: Quick Ratio
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for AVITA MED LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA MED LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.